A. Fabbri

TL;DR: A multicentre, open-label, randomised, phase 3 trial of six different treatments in postmenopausal women with hormone receptor-positive early breast cancer, finding that musculoskeletal side-effects were more frequent with the upfront schedule than with the switch schedule.

TL;DR: Results are comparable with those from randomized trials and further studies are warranted to confirm and interpret the data on apparently lower T-DM1 efficacy when given as second-line treatment after pertuzumab, and on the optimal sequence order.

TL;DR: A case series of 64 synovial sarcomas was characterized for the SYT-SSX fusion transcripts and statistically analysed in order to correlate molecular data with prognosis and morphology.

TL;DR: HBOE study shows that in premenopausal patients with early breast cancer undergoing ovarian function suppression with triptorelin, ZL significantly improves DFS, while worsening compliance and toxicity, as compared with T.

TL;DR: T-DM1 is active in breast cancer patients with BMs and at a median follow-up of 16 months, median cumulative progression-free survival (PFS) was 7 months, and overall survival was 14 months.